Monthly Archives: January 2018

Treatment options for inflammatory bowel disease (IBD) have expended tremendously in the past two decades. Biologics have now been increasingly used early in the course of therapy with the goal of inducing remission and thus delaying or avoiding the n… Continue reading →

Due to the complexity of diagnosis and treatment of Inflammatory bowel disease (IBD), providers observe a large volume of patient inquiries at the Call Center, resulting in a significant investment of time on the part of the providers and support staff… Continue reading →

Rituximab (RTX), an anti-CD20 monoclonal antibody used in treatment of hematologic and rheumatologic disease, depletes systemic and intestinal B-cells. Diarrhea is seen in ∼15% of people. Case reports associated RTX with de novo inflammatory bowel di… Continue reading →

Hypercalcemia has been described in patients with many granulomatous diseases. Elevated serum calcium levels in the setting of granulomatous disease are caused by unregulated production of 1,25-dihydroxyvitamin D by activated macrophages. More commonly… Continue reading →

Lean body mass (LBM) deficits in youth with Inflammatory Bowel Disease (IBD) are well-established and persist despite achievement of remission and restoration of body mass. LBM deficits are associated with both short and long-term health outcomes inclu… Continue reading →

Studies regarding long-term outcomes of adalimumab treatment in non-Caucasian patients with ulcerative colitis (UC) are still lacking. Continue reading →

We have previously demonstrated that gene deletion of the immunosuppressive enzyme IDO1 (indoleamine-2,3-dioxygenase 1) reduces but does not eliminate tumor burden in a mouse model of colitis associated cancer (CAC). In the current study, we test the h… Continue reading →

Current therapies for inflammatory bowel disease (IBD) are aimed at immune suppression. These have not prevented disease progression for the majority of IBD patients and come with consequent risk. There is a recognized need for new, safe and effective … Continue reading →

A disturbed balance between reactivity and tolerance of the intestinal epithelium (IE) to bacterial compounds is one of the key contributors to the IBD pathogenesis. To date, research has mainly focused on the epithelial responses in general, whereas i… Continue reading →

Filgotinib (fil), a selective JAK1 inhibitor, has shown efficacy in a randomized double-blind, placebo (pbo)-controlled phase 2 study in Crohn’s disease (CD) (FITZROY [1]), which included centrally read endoscopy and histopathology assessments after … Continue reading →